Get started
Tesla Reversal Signal Triggered at the 200 SMA!TSLA 🚗 Bullish Pullback Playbook — Smart Layered Entry Setup! 📈 Asset: TSLA — Tesla Inc. (NASDAQ) Swing Trade Playbook | Trend-Continuation Setup 🧠 Market Thesis TSLA shows a bullish pullback into the 200-Day Simple Moving Average, a level historically respected by trend-followers. The latest Heikin-Ashi Doji Reversal signals buyers regaining momentum ⚡ — suggesting the pullback is stabilizing and demand is stepping back in. This combination of trend support + reversal confirmation forms the core of this structured swing setup. 🎯 Plan Overview A clean bullish continuation strategy using a refined layered entry method (professionally framed as “scaled limit entries”). This maintains your signature thief-style energy, but aligned with TradingView rules and presentation standards. 😎 🟢 Entry Plan (Layered / Scaled Limit Orders) Using a scaling approach allows better average pricing during volatility. Proposed buy-limit layers: Buy Limit 1 → $420.00 Buy Limit 2 → $410.00 Buy Limit 3 → $400.00 👉 Traders may increase or reduce the number of layers based on risk tolerance and personal strategy. 🔻 Stop-Loss (Risk Control) A defensive stop-loss is placed near $380.00, below recent liquidity pockets and under the 200 SMA structure. ⚠️ This level is optional — traders should select their own SL based on personal risk management. 🎯 Take-Profit Zone Target area sits around $470.00, where: Major historical resistance awaits Overbought conditions often develop High-volume sellers tend to re-enter This zone is treated as a profit-taking escape point, but traders can exit based on their own judgment. 📡 Related Markets to Watch (Correlation Insight) Keeping the global view helps improve trade confidence: NASDAQ:QQQ — High correlation with mega-cap tech, TSLA often follows Nasdaq momentum. NASDAQ:NDX — Strong tech index correlation; strength supports TSLA continuation. SP:SPX — Broad-market risk sentiment gauge. NASDAQ:NVDA / NASDAQ:AMD — Momentum flow in growth-tech impacts liquidity rotation into TSLA. AMEX:XLY — Consumer Discretionary ETF (TSLA is a major component). Key takeaway: Strong tech-sector momentum + risk-on environment = enhanced TSLA bullish continuation probability 📊⚡ 🧰 Notes for the Community Dear Traders (Thief OG-style Family 😄) — SL/TP levels shared here are only examples for educational purposes. You’re always free to manage your own positions using your own risk preferences. Trade smart, trade safe, trade stylish. 💼✨ ✨ “If you find value in my analysis, a 👍 and 🚀 boost is much appreciated — it helps me share more setups with the community!” This is a thief-style trading strategy presentation strictly for fun and educational purposes. Not financial advice. #TSLA #Tesla #SwingTrade #BullishSetup #LayeredEntries #HeikinAshi #200SMA #NASDAQ #MomentumTrading #TechnicalAnalysis #TradingView #RiskManagement #TraderLifestyle #StockMarket
NASDAQ:TSLA
by The-Thief
1
AG | Silver Miners Will Rise | LONGFirst Majestic Silver Corp. engages in the production, development, exploration and acquisition of mineral properties. It owns and operates producing mines in Mexico including the La Encantada Silver Mine, La Parrilla Silver Mine, San Martin Silver Mine, La Guitarra Silver Mine, Del Toro Silver Mine, Santa Elena Silver & Gold Mine, and San Dimas Silver & Gold Mine. The company was founded by Keith Neumeyer on September 26, 1979 and is headquartered in Vancouver, Canada.
NYSE:AGLong
by DivergenceSeeker
Breaking: Arrowhead Pharmaceuticals, Inc. (ARWR) Spike. 23%Arrowhead Pharmaceuticals, Inc. (NASDAQ: NASDAQ:ARWR ) stock spike 23% amidst earnings beat. The asset broke out of a bullish symmetrical triangle to claim the $50 resistant point after earnings report. Arrowhead Pharmaceuticals ( ARWR) experienced a serious Hump Day jump. On the Wednesday before Thanksgiving, the company's shares rose by more than 23%, thanks largely to its latest earnings release. A flying arrow The previous day at market close, Arrowhead took the wraps off its full-year, fiscal 2025 results. The company's revenue for the period exceeded $829 million, primarily driven by an influx of licensing and collaboration funds, which was significantly higher than the $3.6 million reported in 2024. The most significant event for Arrowhead hasn't been its annual earnings release, though. Earlier this month, the U.S. Food and Drug Administration (FDA) approved its Redemplo for the treatment of adults with familial chylomicronemia syndrome (FCS). This is a rare genetic disorder that impairs the body's ability to metabolize fats. Redemplo is Arrowhead's first FDA nod. Financial Performance In 2025, Arrowhead Pharmaceuticals's revenue was $829.45 million, an increase of 23258.15% compared to the previous year's $3.55 million. Losses were -$1.63 million, -99.73% less than in 2024. About ARWR Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials.
NASDAQ:ARWRLong
by DEXWireNews
Home Depot (HD) - Bullish Setup FormingLast week, HD tested a major support zone and swiftly reversed, signaling strong buying interest at lower levels. This bounce confirms the support's validity and opens the door for a potential continuation to the upside. The structure looks clean, with the bulls stepping back in after a healthy correction. 🔄 We're now watching for a minor pullback into the $347–$350 zone — a key area where price may base before its next leg higher. This would offer a favorable risk-reward opportunity for a long spot trade setup. 🎯 Trade Plan: Entry: $347 – $350 Take Profits: 1️⃣ $365 – $375 2️⃣ $390 – $405 Stop Loss: Just below $331 This setup targets layered exits, managing risk while allowing room for extended gains if momentum continues.
NYSE:HDLong
by Richtv_official
1
Arcus Biosciences (RCUS) — Late-Stage Immuno-Oncology MomentumCompany Overview Arcus NYSE:RCUS is a clinical-stage biotech advancing next-gen cancer & immunology therapies, led by TIGIT inhibitor domvanalimab and HIF-2α inhibitor casdatifan—with growing validation from big-pharma partnerships. Key Catalysts Domvanalimab (TIGIT) — NSCLC Breakthrough: Phase 3 data showed a 37% reduction in progression risk vs. Keytruda, positioning Arcus at the front of a $50B+ immuno-oncology market. Casdatifan (HIF-2α) — Rapid Path in RCC: Advanced to Phase 3 in renal cell carcinoma after ~80% response rates in early trials, reinforcing best-in-class potential. De-Risking Partnerships: Collaborations with AstraZeneca and Gilead provide funding, development scale, and commercial reach across high-value solid tumor indications. Why It Matters ✅ Multiple late-stage shots on goal in large indications ✅ Combination-ready checkpoint assets with clear differentiation ✅ Strategic partners reduce capital & execution risk Investment Outlook Bullish above: $17–$17.50 Target: $32–$33 — supported by Phase 3 TIGIT win, HIF-2α expansion, and partner-enabled commercialization.
NYSE:RCUSLong
by Richtv_official
NVDA vs AVGO: The Battle for the AI Throne Has Begun⚡A New Leader Emerges in the Semiconductors For years, NVDA was the undisputed titan — the gravitational center of the semiconductor universe. But now, the geometry tells a different story. THE CHARTS 📐 Both charts use the same natural scaling: 1° of time = $1 of price per unit. And here’s the critical observation: NVDA has broken beneath its 1° angle. AVGO has recaptured and accelerated above its 1° angle. AVGO has already made new all-time highs. During a semiconductor correction. While SMH was down. While the S&P 500 retraced. The real question still remains however, are we still in the early innings of the AI Boom? SMH — The Semiconductor Supercycle Update The Structure That Defines the AI Era🏛️ The 2023–2027 channel is the master structure for this entire semiconductor cycle. SMH bounced precisely where the primary and secondary angles intersect. 🚀 Market Knots — Speed & Acceleration Confirm the Turn Speed found support precisely at the median line around 126 Market Knots — the natural mid-energy band where major long-term advances restart. Acceleration appears to have: 🔻spiked, 📉bottomed, and is now curling upward. Poised to turn positive The measurements point to a weekly bottom and another wave higher in this semiconductor cycle fueled by AI growth. The Leadership Rotation🏅 (The Baton Moment) AVGO is emerging as the structural leader of the AI supercycle. It has already demonstrated exceptional strength: holding its 1° angle, breaking into new all-time highs, and accelerating while the rest of the semiconductor sector underperformed. This behavior is not random. It reflects Broadcom’s unique position at the infrastructure core of AI — the networking, switching, optical, and custom ASIC layer that becomes the bottleneck after GPUs. As the semiconductor supercycle builds, AVGO steps forward as the defining leader of the AI boom
NASDAQ:NVDA
by Nana-Hermes
8
SMX (Security Matter) Public Limited Company Set for 5000% SurgeThe price of SMX (Security Matters) Public Limited Company (SMX) shares spike nearly 200% yesterday extending the gains to premarket trading currently up 49% in Thursday's premarket session. With the RSI at 36, NASDAQ:SMX is gearing for a 5000% breakout should bullish momentum increase. The stock has been long oversold losing almost 99% of market value. In another news, SMX Turned Six Partnership Deals Into a Global Supply Chain Reset. The past several months have not brought SMX (NASDAQ:SMX) normal momentum. They brought a shift. SMX has been quietly building a year of execution while the rest of the market waited for someone else to lead. Then November arrived, and every part of the story collided at once. Six strategic partnerships were locked in before the 2025 DMCC Precious Metals Conference. Gold identity entered its first true era of scientific verification. Regulators across four continents took notice. And Dubai, the global hub for precious metals, became the stage where the rest of the world finally saw what SMX had already built. This month did not reveal a new idea. It revealed a new baseline. About SMX SMX (Security Matters) Public Limited Company provides brand protection, authentication and track and trace technology for the anti-counterfeit market. Its proprietary marker system embeds a permanent or removable mark on solid, liquid, or gaseous objects or materials. The company’s solutions comprise physical or chemical marker system coupled with a reader and connected to a blockchain digital platform for application in process tracing, authentication, and sustainability and circular economics industries.
NASDAQ:SMXLong
by DEXWireNews
JD.COM is an extremely oversold stockThere’s an interesting situation with JD.com right now. According to the latest report, the company’s net cash position (cash on the balance sheet minus debt) is around $18 billion. At the same time, its stakes in the publicly traded JD Health (~67%) and JD Logistics (~62%) are worth about $25 billion at current market caps. So the combined value of the subsidiaries and the group’s net assets is $43 billion, while the whole company is currently trading at $39 billion. This implies that JD Retail (their core business — the marketplace), JD Industrials, JD Technology, and JD Property are being valued by the market at negative levels. Until last September, there were quite a few companies trading below their cash balances with no debt, and since then many have corrected significantly upward. The fact that JD is once again trading like this is surprising. In my view, the current price can be explained by the following: In September–October, a huge amount of 40-strike calls expiring January 16 were bought — roughly 450,000 contracts, which is enormous (45 million shares against an average daily volume of 16 million). But they couldn’t sustain it, and now this positioning is working against the stock price: the options are decaying, which is putting pressure on the price. Since November the SPX has been volatile, and around 80k contracts were closed; open interest is now 374k — still extremely high. So I think this is purely a technical drawdown that will fade as the options expire. Alternatively, a very strong catalyst would be needed to generate a +30–50% spike in daily volume for delta to “start working.” Today China released a plan for additional stimulus, and JPMorgan upgraded Chinese equities to “overweight,” expecting that AI and economic stimulus will be the key drivers in 2026.
NASDAQ:JDLong
by ati1981
1
COSTCO may be the most durable choice in this Bear Cycle.Costco (COST) has been trading within a 17-year Channel Up ever since the 2008 Housing Crisis. Since its June 2025 High, it has been on a steady decline, contrary to the big gains of other high cap stocks (mainly tech). During this decline, it has broken below its 1W MA50 (blue trend-line), which has been the main Support of the Bull Cycle since May 2023, confirming its Bear Cycle. However, it just hit its 1W MA100 (green trend-line), a critical level as it is the one that not only formed the bottom of the 2022 Bear Cycle but has also been holding since September 2017, providing numerous excellent buy entry opportunities. With the 1M RSI also approaching its 9-year Support Zone, we believe that Costco may be one of the most durable stock investment choices during the upcoming Bear Cycle on stock indices. The Sine Waves are laying out a rather solid mapping of key market top formation periods long-term and we are currently far from one. The 17-year Channel Up is currently on its 3rd major Bullish Leg and remarkably enough the previous two both rose by the exact same percentage, 347.16%. If the current Bullish Leg repeats that from its 2022 bottom, then we can expect this stock to reach $1800 around 2028. --- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** --- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NASDAQ:COSTLong
by TradingShot
1
TWST bull ready to unleash?Genomics: The Next Decade’s Most Underpriced Revolution? If you had to pick one scientific field with the potential to redefine medicine, agriculture, and consumer health over the next decade, genomics should be at the top of the list. At its core, genomics is the study of the entire genetic code—our DNA—and how it influences everything from disease risk to drug response to crop resilience. Modern genomics companies offer far more than ancestry reports. The industry now spans three major pillars: 1. Genetic sequencing and analysis. 2. Personalised health and diagnostics. 3. Therapeutics and gene editing. What's going for the Genomic Industry now heading into 2026 vs crushing years following 2021: Regulation is maturing. The FDA is warming to gene-edited therapies, and reimbursement frameworks are slowly aligning with personalised medicine. Costs are collapsing. Sequencing is approaching the “$10 genome,” unlocking applications that were previously uneconomical. AI accelerates discovery. Large-scale biological datasets are exactly the domain where AI thrives, shrinking timelines for drug development and variant interpretation. In terms of current rating, we anticipate momentum may shift to a 'bullish' reading if price can push and hold above $38.00 and note significant risk should price fall below the $27.50 mark. We're inspired to bring you the latest developments across worldwide markets, helping you look in the right place, at the right time. Thank you for reading! Stay tuned for further updates, and we look forward to being of service along your trading & investing journey... Disclaimer: As always, please note all information contained within this post and all other Bullfinder-official Tradingview content is strictly for informational purposes only and is not intended to be investment advice. Please DYOR & Consult your licensed financial advisors before acting on any information contained within this post, or any other Bullfinder-official TV content.
NASDAQ:TWSTLong
by Bullfinder-official
Tesla (TSLA) – Technical Analysis OverviewHello friends, I haven't shared an analysis for a long time. I'm back in the market. Don't forget to follow me for my regular analysis. The chart shows that Tesla continues to hold its medium-term upward trend. The price recently tested the 408–410 support zone, which aligns with the rising trend line, and has reacted from that level. This area is technically significant, as it coincides with both trend support and a region where short-term liquidity has accumulated. On the upside, the first notable resistance appears around 462–465. The projected ~13% potential move on the chart also points toward this region, suggesting that a rebound toward this level is plausible as long as the trend support remains intact. Looking at the indicators: RSI is currently within the 41–48 range, not in oversold territory but reflecting weakened momentum. This supports the idea that price is stabilising near a meaningful support area. MACD remains in negative territory, indicating that bullish momentum has not fully recovered yet. A clearer shift toward the zero line would help confirm any sustained upward move. In summary: * The 408–410 zone is acting as a solid support. * The broader trend structure remains intact and upward. * 462–465 is the first major target area. * However, momentum indicators are still soft, so confirmation through stronger candles would be constructive. Volatility may remain elevated in the short term, but as long as the price stays above trend support, upward attempts appear more likely. Disclaimer: This is a technical assessment only and does not constitute investment advice.*
NASDAQ:TSLALong
by celilADIGUZEL
2
Breaking: Pasithea Therapeutics Corp. (KTTA) Up 117% YesterdayPasithea Therapeutics Corp. (NASDAQ: NASDAQ:KTTA ) stock saw a noteworthy uptick of 117% amidst market dip. The stock bounced from the $0.30 support to claim the $1 resistant albeit market turmoil. With the RSI at 67, the stock is looking poised for a continuation trend should it break the 38.2% fib level. On a bearish tone, the asset is down 12% in Thursday's premarket trading. In another news, Pasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients, with Positive Safety, Pharmacokinetic (PK), and Pharmacodynamic (PD) Data About KTTA Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumors; and ETS2 driven diseases, including inflammatory bowel disease (IBD).
NASDAQ:KTTALong
by DEXWireNews
Is Boeing's Defense Bet America's New Arsenal?Boeing's recent stock appreciation stems from a fundamental strategic pivot toward defense contracts, driven by intensifying global security tensions. The company has secured major wins, including the F-47 Next Generation Air Dominance (NGAD) fighter contract worth over $20 billion and a $4.7 billion deal to supply AH-64E Apache helicopters to Poland, Egypt, and Kuwait. These contracts position Boeing as central to U.S. military modernization efforts aimed at countering China's rapid expansion of stealth fighters like the J-20, which now rivals American fifth-generation aircraft production rates.   The F-47 program represents Boeing's redemption after losing the Joint Strike Fighter competition two decades ago. Through its Phantom Works division, Boeing developed and flight-tested full-scale prototypes in secret, validating designs through digital engineering methods that dramatically accelerated development timelines. The aircraft features advanced broadband stealth technology and will serve as a command node controlling autonomous drones in combat, fundamentally changing air warfare doctrine. Meanwhile, the modernized Apache helicopter has found renewed relevance in NATO's Eastern flank defense strategy and counter-drone operations, securing production lines through 2032.   However, risks remain in execution. The KC-46 tanker program continues facing technical challenges with its Remote Vision System, now delayed until 2027. The F-47's advanced variable-cycle engines are two years behind schedule due to supply chain constraints. Industrial espionage, including cases where secrets were sold to China, threatens technological advantages. Despite these challenges, Boeing's defense portfolio provides counter-cyclical revenue streams that hedge against commercial aviation volatility, creating long-term financial stability as global rearmament enters what analysts describe as a sustained "super-cycle" driven by great power competition.
NYSE:BALong
by UDIS_View